Does Medica Cover Prolia? Coverage Rules, Costs, and What to Do If Denied

What Is Prolia and Why Does Coverage Status Matter?

Prolia is the brand name for denosumab 60 mg, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), a protein that drives osteoclast formation and bone resorption. The FDA approved Prolia in June 2010 for postmenopausal women at high fracture risk, and the label has since expanded to include men with osteoporosis, patients on long-term glucocorticoid therapy, and patients experiencing bone loss from hormone ablation therapy for prostate or breast cancer 1.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared to placebo over 36 months 2. Those efficacy figures explain why clinicians consider it a first-line or second-line option for high-risk patients, and they also explain why payers scrutinize the drug carefully. At a list price near $1,900 per injection, two doses per year creates a roughly $3,800 annual drug cost before discounts, which places it squarely in specialty tier territory for nearly every commercial insurer, including Medica.

Because Prolia is administered by injection in a clinical setting rather than taken as an oral tablet, it may be billed under either the medical benefit (procedure code J0897) or the pharmacy benefit depending on the Medica plan. That distinction matters enormously for cost sharing, which is explained in detail below 3.

How Medica Structures Its Drug Formularies

Medica Health Plans operates across Minnesota and several neighboring states, offering commercial employer-sponsored plans, individual and family plans on the ACA marketplace, Medicare Advantage plans, and Medicaid-managed care (Medica with Minnesota Health Care Programs). Each product line maintains a separate formulary, and Prolia's placement and coverage criteria differ across them 4.

Commercial and employer plans. Most Medica commercial plans place Prolia on Tier 4 or Tier 5 (specialty). Copays at this tier typically run from $100 to $300 per fill, though some high-deductible plans require the member to pay the full negotiated cost until the deductible is met. The plan's specialty pharmacy network may also restrict where the drug can be dispensed.

Medicare Advantage plans. Medica offers several Medicare Advantage products under names such as Medica Prime, Medica AccessAbility, and Medica with Essentials. On these plans, Prolia is often covered under Part B when administered in a physician's office (J0897 billed at 80% after deductible) or under Part D specialty tiers when dispensed through a specialty pharmacy. CMS data show that Part B cost sharing for denosumab averages $190-$380 per injection in Medicare Advantage plans after cost sharing, depending on whether the patient has reached out-of-pocket limits 5.

Medicaid (Minnesota Health Care Programs via Medica). Minnesota Medicaid covers Prolia for medically necessary indications, but prior authorization is required and criteria are strict. The preferred agents are generic alendronate and risedronate first.

The table below outlines a simplified decision framework for understanding which benefit bucket applies:

| Setting | Billing Code | Typical Benefit | Medica Cost Sharing | |---|---|---|---| | Physician office injection | J0897 (medical benefit) | Part B or medical | 20% coinsurance after deductible | | Specialty pharmacy dispense | NDC (pharmacy benefit) | Specialty tier | Tier 4-5 copay or coinsurance | | Hospital outpatient injection | J0897 bundled | Outpatient facility | Facility fee plus drug coinsurance |

Always confirm with Medica Member Services (1-800-952-3455) which bucket applies to your specific plan before the injection is administered. A mismatch between billing and benefit can result in a claim denied as a coordination error.

Prior Authorization Requirements for Prolia on Medica Plans

Prior authorization (PA) is required for Prolia on nearly every Medica plan. Submitting an incomplete PA request is the most common reason for initial denial, so understanding exactly what documentation is needed saves weeks of delay.

Medica's PA criteria for Prolia generally mirror the clinical evidence and the American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines, which stratify fracture risk as moderate, high, and very high 6. Medica typically requires the prescriber to document at least one of the following:

1. A DXA scan result showing a T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck.
2. A documented low-trauma (fragility) fracture, defined as a fracture resulting from a fall from standing height or less, in a patient with osteopenia (T-score between -1.0 and -2.5).
3. A 10-year major osteoporotic fracture probability at or above 20%, or a 10-year hip fracture probability at or above 3%, calculated using the FRAX tool 7.
4. A contraindication to oral bisphosphonates such as Barrett esophagus, inability to remain upright for 30 minutes, or severe renal impairment (eGFR <35 mL/min/1.73 m2).
5. Documented intolerance to bisphosphonates after an adequate trial (typically defined as 6-12 months of alendronate 70 mg weekly or risedronate 35 mg weekly).

The PA form must include the prescriber's NPI, the patient's diagnosis code (M81.0 for postmenopausal osteoporosis is most common), the relevant DXA values with the scan date, and the FRAX score if used. Labs such as serum calcium and vitamin D 25-OH are sometimes requested to confirm the patient is replete before starting denosumab, consistent with FDA label guidance 1.

Approvals are typically valid for 12 months, covering two injections. Renewal PA is required annually and must document clinical response (ideally stable or improved DXA T-score) and absence of serious adverse events such as osteonecrosis of the jaw or atypical femoral fracture.

Step Therapy: Do You Have to Try a Bisphosphonate First?

For most patients who do not have a documented contraindication or intolerance, Medica applies step therapy, requiring a documented trial of an oral bisphosphonate before Prolia will be authorized. The most commonly required agents are alendronate 70 mg once weekly (generic cost: approximately $10-$15 per month) and risedronate 35 mg once weekly 8.

Step therapy is clinically defensible. Alendronate has been shown in the FIT trial (N=2,027 hip fracture arm; N=4,432 vertebral fracture arm) to reduce vertebral fracture risk by approximately 47% and hip fracture risk by approximately 51% in women with prior vertebral fracture and low bone density 9. Generic alendronate costs roughly 1-2% of Prolia's list price annually, making it a rational first step for patients who can tolerate it.

However, step therapy has real limitations. A 2019 analysis published in Osteoporosis International found that approximately 30% of patients prescribed oral bisphosphonates discontinue within 12 months due to gastrointestinal side effects, including esophageal irritation, nausea, and abdominal pain 10. For those patients, documented intolerance is a valid step therapy exemption, and the prescriber should record specific symptoms with dates in the medical record.

Patients who fall into very high fracture risk categories may qualify for a step therapy exemption even without a prior bisphosphonate trial. The AACE guidelines define very high risk as a recent fragility fracture (within the past 12 months), T-score at or below -3.0, or FRAX 10-year major osteoporotic fracture probability at or above 30% 6. Submitting the AACE very-high-risk criteria alongside the PA request may bypass step therapy requirements.

Minnesota state law (Minn. Stat. Section 62Q.184) includes step therapy override protections. A prescriber can request a step therapy exemption if the required drug is clinically contraindicated, if the patient previously failed or was intolerant of the required drug, or if the required drug would cause adverse interaction with another drug the patient is taking. Medica must respond to a step therapy exemption request within 72 hours (or 24 hours for urgent requests) 11.

What Prolia Actually Costs on Medica After Coverage

Out-of-pocket cost on Medica depends on which benefit applies and where in your plan year you are.

Early in the deductible year. If you are on a high-deductible plan and have not met your deductible, you may owe the full negotiated rate for Prolia, which after insurer discounts from Amgen typically runs $1,200-$1,600 per injection. This is a significant one-time expense, but it counts toward your deductible.

After deductible. Most commercial Medica plans apply a coinsurance rate of 20-40% for specialty tier drugs once the deductible is met. On a negotiated rate of $1,400 per injection, 30% coinsurance equals $420 per dose. Two doses per year means $840 in Prolia cost sharing alone, before considering other medications.

Medicare Advantage. Under Part B billing, Medicare standard cost sharing is 20% after the Part B deductible ($240 in 2024). Medica's Medicare Advantage plans may reduce this further to a fixed copay per injection. The best approach is to call Medica Medicare Member Services and ask specifically what the Part B specialty drug copay is for HCPCS code J0897.

Amgen patient assistance. Amgen's AMGENSUPPORTPLUS program (formerly Prolia Assist) offers the drug at no cost for commercially insured patients who meet income eligibility requirements (generally at or below 500% of the federal poverty level) and for uninsured patients. Even for patients above income thresholds, Amgen provides copay assistance cards that can reduce commercial plan cost sharing significantly. Patients can enroll at 1-888-4PROLIA or through their prescriber's office.

How to Appeal a Medica Denial for Prolia

Medica must follow federal and state grievance and appeals timelines. For a standard (non-urgent) prior authorization denial, Medica must issue a written decision within 30 days of the request. For urgent situations where delay could harm the patient, the timeline is 72 hours 12.

If Prolia is denied, the prescriber should take the following steps:

Step 1: Request the specific denial reason in writing. Medica is required to provide the clinical criteria used and the specific reason the request did not meet them. Common denial reasons include insufficient DXA documentation, no documented bisphosphonate trial, or missing FRAX score.

Step 2: File an internal appeal with additional clinical documentation. The appeal should include a letter of medical necessity from the prescribing physician, the relevant DXA reports with T-scores, FRAX calculation printout, any documentation of bisphosphonate intolerance, and relevant peer-reviewed literature (the FREEDOM trial 2 and the AACE 2020 guidelines 6 are particularly useful).

Step 3: Request a peer-to-peer review. Most insurers, including Medica, allow the prescribing physician to speak directly with the plan's medical reviewer. This conversation often resolves denials faster than written appeals. The prescriber should reference specific guideline citations and patient-specific fracture risk data.

Step 4: Request external review if the internal appeal is denied. Under Minnesota law and the ACA, patients have the right to an independent external review of any denial. External reviewers overturn insurer decisions in a meaningful percentage of specialty drug cases. CMS data from 2023 show that approximately 50-60% of Medicare Part D specialty drug appeals are resolved in the enrollee's favor 13.

Step 5: Contact the Minnesota Department of Commerce. If Medica is not following required timelines or is applying criteria inconsistent with clinical evidence, the Minnesota Department of Commerce Insurance Division (651-539-1500) accepts consumer complaints and can intervene.

Special Situations: Glucocorticoid-Induced Osteoporosis and Oncology Indications

Prolia carries distinct FDA-approved indications beyond standard postmenopausal osteoporosis, and Medica's coverage criteria differ slightly for each 1.

Glucocorticoid-induced osteoporosis (GIOP). For patients on systemic glucocorticoids at a dose of 7.5 mg prednisone equivalent or higher for 6 months or more, denosumab is an option when fracture risk is high. The American College of Rheumatology 2022 guidelines for GIOP recommend treating high-risk patients (those with a prior fragility fracture, T-score at or below -2.5, or high FRAX scores) with an anabolic or antiresorptive agent, and denosumab is listed as an acceptable antiresorptive choice 14. For a Medica PA in GIOP, the documentation must include the glucocorticoid agent, dose, and duration alongside fracture risk assessment.

Hormone ablation bone loss. Men with prostate cancer on androgen deprivation therapy (ADT) and women with breast cancer on aromatase inhibitors experience accelerated bone loss. Prolia 60 mg every 6 months is FDA-approved for bone loss prevention in these populations 1. Medica may route these cases through oncology benefits rather than standard pharmacy benefits, which can change the cost-sharing structure. Confirm with Medica whether the oncology team's office should bill J0897 under the oncology plan benefit.

Note that Xgeva (denosumab 120 mg every 4 weeks) is a separate product for prevention of skeletal-related events in bone metastases. Xgeva and Prolia are not interchangeable in dosing, indication, or coverage routing. A request for Prolia coverage will not automatically cover Xgeva, and vice versa 15.

Discontinuing Prolia: The Rebound Risk Medica Coverage Should Account For

One aspect of Prolia coverage that patients and prescribers must understand before starting therapy is the rebound phenomenon. When denosumab is discontinued without transitioning to a bisphosphonate, bone turnover markers rebound to above-baseline levels within months, and multiple vertebral fractures can occur rapidly 16. A 2017 study published in the Journal of Bone and Mineral Research (N=1,001 denosumab-treated patients from the FREEDOM extension) documented that patients who stopped denosumab without a subsequent antiresorptive had vertebral fracture rates returning to placebo levels or higher within 12 months of discontinuation 16.

This means that a coverage gap, whether from a denied PA renewal, a plan change, or a lapse in Amgen assistance enrollment, is not simply an inconvenience. It is a clinical hazard. Patients approaching their 6-month injection window who have not yet received PA renewal approval should contact Medica's pharmacy benefit management team at least 60 days before the injection due date. Prescribers should note in PA renewal requests that abrupt discontinuation carries documented fracture risk, citing the FREEDOM extension data 16, to underscore medical necessity for uninterrupted coverage.

If coverage cannot be secured in time, the prescriber should consider bridging with zoledronic acid 5 mg IV infusion, which has been studied as a post-denosumab transition agent and may attenuate the rebound in bone resorption markers 17.

Key Documents to Gather Before Calling Medica

Having the right paperwork ready before contacting Medica cuts the PA timeline substantially. Gather the following before the first call or portal submission:

• The most recent DXA report (dual-energy X-ray absorptiometry) showing T-scores at the lumbar spine and total hip, with the scan date.
• FRAX calculation output (available free at sheffield.ac.uk/FRAX), including country, age, sex, body weight, height, prior fracture history, parental hip fracture, current smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol use inputs.
• Records of any prior bisphosphonate therapy, including start date, end date, dose, and reason for stopping.
• Prescriber's letter of medical necessity on office letterhead, citing specific T-score values and FRAX probabilities.
• Serum 25-hydroxyvitamin D and calcium results from within the past 12 months.
• Medica member ID number and group number from the insurance card.

Submitting all documents simultaneously at PA initiation, rather than responding piecemeal to information requests, reduces average PA processing time from a potential 30-day window to a more typical 5-10 business days in practice.